Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ESCAPE-SHF: A Double-blind, Double-dummy, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Systolic Heart Failure
Brief Summary: In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level. An increase of angiotensin II is associated with progression of heart failure. Although the use of ACE-inhibitors in heart failure shows clinical benefit, an increase in angiotensin II due to an angiotensin II "escape" phenomenon is not desirable. It is not yet known if a direct renin inhibitor can reduce or even prevent the angiotensin II escape phenomenon associated with the use of an ACE-inhibitor. Therefore the study tested the effects of ramipril, aliskiren and the combination of both on levels of angiotensin II in the blood in patients with systolic heart failure


Options:
A: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: aliskiren, Drug: ramipril, Drug: Placebo to ramipril | Arm Label: Ramipril; Type: EXPERIMENTAL; Interventions: Drug: ramipril, Drug: Placebo to aliskiren | Arm Label: Aliskiren plus Ramipril; Type: EXPERIMENTAL; Interventions: Drug: aliskiren, Drug: ramipril | Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): Aliskiren, Aliskiren plus Ramipril | Intervention Type: DRUG; Name: ramipril; Assigned to Arm(s): Aliskiren, Aliskiren plus Ramipril, Ramipril | Intervention Type: DRUG; Name: Placebo to aliskiren; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Placebo to ramipril; Assigned to Arm(s): Aliskiren
B: Arm Label: Aliskiren-based regimen; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide, Drug: Amlodipine | Arm Label: Ramipril-based regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Hydrochlorothiazide, Drug: Amlodipine | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren-based regimen | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril-based regimen | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MK8141 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Intervention Type: DRUG; Name: MK8141; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 3
D: Arm Label: Combination Aliskiren / Enalapril; Type: EXPERIMENTAL; Interventions: Drug: Enalapril, Drug: Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Combination Aliskiren / Enalapril, Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren, Combination Aliskiren / Enalapril

Answer: A